Return to homepagePandemic Pact

Defective viral genomes (DVGs), potential antiviral inhibitors of SARS-CoV-2 (SARS-DVGs project)

  • Funded by Institut Pasteur International Network (IPIN)
  • Total publications:0 publications

Grant number: SARS-DVGs

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    Institut Pasteur International Network (IPIN)

  • Research Location

    France

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Aim: to use a pipeline to identify the best DVG candidates (molecules known to inhibit viral populations). The pipeline has proven effective in several virus families such as the MERS and murine (MHV) coronaviruses. The scientists propose to use the same method for SARS-CoV-2 and to test the five best DVG candidates on cell cultures. This could lead to DVGs being brought to market as an antiviral treatment for SARS-CoV-2.DVGs are defective viral genomes capable of hijacking the replication machinery of wild-type viruses and partially or totally inhibiting viral populations. Thousands of different DVGs are produced during infection by one of these viruses. The scientists have developed a method to select those most likely to have antiviral potential.